Venlafaxine versus mirtazapine in the treatment of undifferentiated somatoform disorder - A 12-week prospective, open-label, randomized, parallel-group trial
- Authors
- Han, Changsu; Pae, Chi-Un; Lee, Bun-Hee; Ko, Young-Hoon; Masand, Prakash S.; Patkar, Ashwin A.; Joe, Sook-Haeng; Jung, In-Kwa
- Issue Date
- 2008
- Publisher
- ADIS INT LTD
- Keywords
- Mirtazapine, therapeutic use; Somatoform disorders; Venlafaxine, therapeutic use
- Citation
- CLINICAL DRUG INVESTIGATION, v.28, no.4, pp.251 - 261
- Indexed
- SCIE
SCOPUS
- Journal Title
- CLINICAL DRUG INVESTIGATION
- Volume
- 28
- Number
- 4
- Start Page
- 251
- End Page
- 261
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/125606
- DOI
- 10.2165/00044011-200828040-00006
- ISSN
- 1173-2563
- Abstract
- Objective: We set out to compare the efficacy and tolerability of mirtazapine versus venlafaxine in patients with undifferentiated somatoform disorder (USD) using the Patient Health Questionnaire-15 (PHQ-15). Methods: This was a 12-week prospective, open-label, randomized, parallel-group trial. The trial consisted of six visits that included baseline and weeks 1, 2, 4, 8 and 12. The primary effectiveness measure was the mean change in PHQ-15 total score from baseline to the end of treatment. Secondary effectiveness measures included the mean changes in total scores on the Beck Depression Inventory (BDI) and the 12-item General Health Questionnaire (GHQ) from baseline to the end of treatment. Ninety-five subjects were randomized to either mirtazapine (n =50) or venlafaxine (n = 45); 71 subjects completed the study (mirtazapine: n=39/50 [78%]; venlafaxine: n = 32/45 [71%]). Results: The mean total score on the PHQ-15 decreased by 34.7% (-8.4, p < 0.0001) from baseline to endpoint in the mirtazapine group and by 26.6% (-6.1, p < 0.0001) in the venlafaxine group. A marginally significant between-group difference was observed for the mean change in total score on the PHQ-15 from baseline to endpoint (F = 4.126, p = 0.046). The mean total scores on the GHQ-12 and BDI from baseline to endpoint decreased by -4.9 (29.4%, p < 0.0001) and -13.5 (55.9%, p < 0.0001), respectively, in the mirtazapine group, and by -4.3 (26.2%, p = 0.001) and -9.02 (46.0%, p < 0.0001), respectively, in the venlataxine group. No between-group difference was observed for the mean changes in total scores on the secondary effectiveness measures from baseline to endpoint. Both treatments were well tolerated. Conclusion: Our findings suggest that both mirtazapine and venlafaxine may be effective and well tolerated in the treatment of patients with USD. Double-blind, placebo-controlled and/or head-to-head comparison studies are required to allow definite conclusions to be drawn.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Medical Science > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.